Q3 revenue rose 8.4% at constant currency and adjusted EBITDA grew 9.8%, with 9M free cash flow at EUR 298m and leverage below 4x. Guidance remains on track, while China albumin weakness and Q4 comparisons temper near-term growth.
Based on Grifols, S.A. Class A [GRF] Q3 2026 Audio Transcript — Nov. 2 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr
